Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.36.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.134NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.39.1.3 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.3.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Q.2 (Alpha)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
M.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.5.6 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.440NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.23.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.104 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.198NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAFNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BC.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.48NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.10.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-21588.8US
BA.5.2.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.9.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.6.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.34NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CE.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XGNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EF.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XPNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DN.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CQ.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used